Corvus Pharmaceuticals Quarterly Balance Sheet
NASDAQ: CRVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Corvus Pharmaceuticals financial position
As of Jun 30, 2026, Corvus Pharmaceuticals reported total assets of $239.3 million, up 167.5% from a year earlier against total liabilities of $13.9 million. Shareholders' equity stood at $225.3 million, or 94.2% of assets. The company held $18.9 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 16.16, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Corvus Pharmaceuticals balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 18.91M | 40.10M | 4.58M | 2.87M | 14.69M | 5.00M | 8.74M | 4.68M | 14.84M | 7.46M | 12.62M | 20.11M |
| Short-Term Investments | 196.32M | 196.61M | 52.17M | — | — | — | 43.22M | — | — | — | — | — |
| Receivables | 6.00K | 43.00K | 37.00K | 32.00K | 86.00K | 79.00K | 75.00K | 70.00K | 35.00K | 26.00K | 26.00K | 11.00K |
| Total Current Assets | 220.97M | 239.95M | 58.21M | 66.94M | 75.78M | 45.49M | 54.41M | 42.92M | 48.26M | 22.85M | 27.96M | 33.09M |
| Property, Plant & Equipment | 830.00K | 282.00K | 220.00K | 221.00K | 249.00K | 165.00K | 151.00K | 171.00K | 192.00K | 213.00K | 236.00K | 264.00K |
| Total Assets | 239.27M | 253.19M | 71.12M | 80.47M | 89.46M | 59.44M | 68.91M | 58.81M | 64.56M | 40.08M | 45.55M | 51.94M |
| Accounts Payable | 4.05M | 4.70M | 2.49M | 1.97M | 3.14M | 1.31M | 2.58M | 1.87M | 1.21M | 1.61M | 1.52M | 1.40M |
| Total Current Liabilities | 13.67M | 12.11M | 9.38M | 8.07M | 8.51M | 9.28M | 35.40M | 46.41M | 13.34M | 6.72M | 6.87M | 7.30M |
| Total Liabilities | 13.95M | 12.52M | 9.91M | 8.71M | 9.23M | 10.11M | 36.34M | 46.41M | 13.34M | 6.72M | 6.87M | 7.65M |
| Shareholders' Equity | 225.33M | 240.68M | 61.20M | 71.77M | 80.23M | 49.33M | 32.57M | 12.41M | 51.23M | 33.36M | 38.68M | 44.29M |
| Retained Earnings | -443.94M | -425.99M | -412.29M | -399.97M | -389.81M | -381.82M | -397.01M | -384.90M | -344.68M | -340.42M | -334.72M | -328.06M |
| Net Cash (Debt) | 215.23M | 236.71M | 56.75M | 2.87M | 14.69M | 5.00M | 51.96M | 4.68M | 14.84M | 7.46M | 12.62M | 20.11M |
| Shares Outstanding | 84.12M | 84.09M | 74.70M | 74.68M | 74.51M | 68.17M | 67.90M | 62.58M | 62.55M | 49.04M | 49.04M | 49.04M |
This table shows 12 quarterly periods of Corvus Pharmaceuticals's balance sheet, from Q2 2026 back to Q3 2023, across 13 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow CRVS's reporting calendar. What is a balance sheet?